IMS buys clinical trials support software firm
IMS says that by integrating its information on healthcare outcomes, providers and patients with DecisionView’s technology, it will be able to help clinical trial sponsors base their site selection and patient enrolment decisions on real-world data and benchmarks.
“Approximately 90% of clinical trials don’t finish on time, with trial enrolment cited as as the leading cause of delays,” said Andrew Kress, senior vice president of IMS Heathcare Value Solutions (HVS). “Through this acquisition we will enhance clinical trial productivity.”
DecisionView becomes part of HVS. President and CEO Linda Drumright (pictured) remains with the business.
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments